GSK : US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer
MarketScreener,
US FDA also recently granted Fast Track designation to Jemperli in this patient population GSK plc (LSE/NYSE: GSK) today…